Intensity Therapeutics Discounted Cash Flow

Intensity Therapeutics (INTS) currently reports a DCF fair value of $8.7. Use the charts on this page to explore Intensity Therapeutics's DCF fair value history and peer comparisons.

Intensity Therapeutics's discounted cash flow (DCF) fair value estimate is $8.7, about 172.1% undervalued versus the current market price. DCF models project future free cash flows and discount them back to today — so the result depends on growth, margin, and discount-rate assumptions. Use it as one valuation lens alongside multiples and peer checks on Stockcircle.

Start with the current DCF fair value of $8.7, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intensity Therapeutics, and consider following INTS for alerts when major investors trade the stock.